Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Chimeric antigen receptor T-cell (CAR‑T) therapy targeting B‑cell maturation antigen (BCMA) is now a standard of care for relapsed and refractory multiple myeloma (MM) with two approved drug products (i.e., idecabtagene vicleucel [ide‑cel], ciltacabtagene autoleucel [cilta‑cel]).
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy
- Reaching Consensus on Defining, Treating High‑Risk Myeloma